Neurocrine Biosciences (NBIX) EBIT Margin (2010 - 2026)

Neurocrine Biosciences has reported EBIT Margin for 16 years, with the latest figure at 23.74% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 1962.0% year-over-year to 23.74%; the trailing twelve-month figure through Mar 2026 stood at 25.43% (up 492.0% YoY), and the FY2025 full-year result was 21.64%, down 258.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 23.74%, down from 26.18% in the prior quarter.
• The five-year high for EBIT Margin was 273.5% in Q2 2022, with the low at 27.16% in Q1 2023.
• Historically, EBIT Margin has averaged 33.54% across 5 years, with a median of 23.74% in 2026.
• Annual changes were most pronounced in 2022 — EBIT Margin jumped 25176 bps — and 2023, when it slumped 25724 bps.
• Neurocrine Biosciences' EBIT Margin stood at 25.1% in 2022, then climbed by 16 bps to 29.17% in 2023, then decreased by 22 bps to 22.62% in 2024, then climbed by 16 bps to 26.18% in 2025, then declined by 9 bps to 23.74% in 2026.
• The last three EBIT Margin figures came in at 23.74% (Q1 2026), 26.18% (Q4 2025), and 30.07% (Q3 2025), per Business Quant data.